Holen Sie sich die Stockscreener-App
49.11
0.95%
-0.47
Handel nachbörslich:
49.30
0.19
+0.39%
Schlusskurs vom Vortag:
$49.58
Offen:
$49.1
24-Stunden-Volumen:
4.79M
Relative Volume:
1.15
Marktkapitalisierung:
$5.56B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-52.81
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
-22.01%
1M Leistung:
-25.36%
6M Leistung:
-26.70%
1J Leistung:
+335.76%
1-Tages-Spanne:
$47.65
$50.51
1-Wochen-Bereich:
$47.65
$62.50
52-Wochen-Spanne:
$11.21
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VKTX | 49.11 | 5.56B | 0 | -99.15M | -74.25M | -0.93 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics (NASDAQ:VKTX) Shares Down 1.4%Here's What Happened - MarketBeat
What the Options Market Tells Us About Viking Therapeutics - Benzinga
3 Things You Need to Know if You Buy Viking Therapeutics Today - sharewise
Viking Therapeutics Insiders Sold US$8.9m Of Shares Suggesting Hesitancy - Simply Wall St
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives $109.80 Average PT from Brokerages - MarketBeat
Is It Too Late to Buy Viking Therapeutics Stock? - sharewise
3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia) - AOL
LJI Wealth Management LLC Has $1.17 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On. - AOL
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On. - The Motley Fool
Viking Therapeutics (NASDAQ:VKTX) Shares Down 2.9%Should You Sell? - MarketBeat
Market Whales and Their Recent Bets on VKTX Options - Benzinga
Oppenheimer & Co. Inc. Has $6.48 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Trading Down 1%Should You Sell? - MarketBeat
Aptus Capital Advisors LLC Purchases 9,699 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Sigma Planning Corp Acquires Shares of 15,119 Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand? - Yahoo! Voices
Viking Therapeutics (NASDAQ:VKTX) Shares Down 3.1%Here's Why - MarketBeat
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly? - sharewise
Chartwell Investment Partners LLC Acquires 17,159 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Is Viking Therepautics a Buy Now? - AOL
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 5.6%What's Next? - MarketBeat
Viking Therapeutics to Present Key NASH Drug Trial Results at Major Liver Meeting | VKTX Stock News - StockTitan
Viking Therapeutics (VKTX) Shares Cross Below 200 DMA - Nasdaq
Principal Financial Group Inc. Has $37.58 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Trading Down 2.2% After Insider Selling - MarketBeat
Is Viking Therapeutics a Buy on the Dip? - sharewise
291,318 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Purchased by Fiera Capital Corp - MarketBeat
Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) Director Sells 2,000 Shares of Stock - MarketBeat
Viking Therapeutics director sells $137,333 in stock - Investing.com
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.8%What's Next? - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) is Quantum Private Wealth LLC's 10th Largest Position - MarketBeat
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move - sharewise
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat - MSN
Viking Therapeutics (NASDAQ:VKTX) Shares Up 0.3%Time to Buy? - MarketBeat
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag - MSN
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial - MSN
Viking Therapeutics (VKTX) Stock Surges on Promising Treatment Pipeline - Nasdaq
Viking Therapeutics Shines With Promising Results For New Obesity Drug - Finimize
Viking Therapeutics reports positive data from trial of treatment for rare metabolic disorder X-ALD - MSN
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
Viking Therapeutics Offers An Obesity Drug for Healthy Adults - Yahoo Finance
Viking stock fluctuates amid manufacturing concerns with obesity pill - Clinical Trials Arena
AlphaCentric Advisors LLC Trims Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data - MSN
Viking Tops Novo As Obesity Pill Brawl Continues; But Shares Slash Massive Gains - MSN
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations - MSN
Vanguard Group Inc's Strategic Acquisition in Viking Therapeutics - GuruFocus.com
Why Viking Therapeutics Stock Plummeted After Soaring Today - sharewise
Viking Therapeutics soars then drops on obesity data - MSN
Stocks to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel - The Wall Street Journal
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):